Alnylam Pharmaceuticals | ALNY - Equity Capital And Reserves



Alnylam Pharmaceuticals reported $250.59M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
Arrowhead Research USD 522.31M 161.91M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Moderna USD 9.4B 667M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 1.99B Jun/2025
PTC Therapeutics USD -206546000 20.79M Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Sanofi 70.28B 7.58B Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
Takeda JPY 6.87T 69.82B Jun/2025
Tectonic Therapeutic USD 283.77M 142.99M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025
Xencor USD 620.35M 19.52M Jun/2025